Cytokinetics (CYTK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$72.72-1.66%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CYTK
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 67.7 | 88.0 | 18.5 | 7.5 | 94.6 | 70.4 | 55.8 | 26.9 | 31.5 | 13.4 | 106.4 | 28.7 | 46.9 | 30.6 | 7.6 | 4.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 13.4 | 106.4 | 28.7 | 46.9 | 30.6 | 7.6 | 4.0 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 401.0 | 416.0 | 339.4 | 330.1 | 240.8 | 159.9 | 97.0 | 86.1 | 89.1 | 90.3 | 59.9 | 46.4 | 44.4 | 49.5 | 35.6 | 37.2 |
| Operating Income | (707.9) | (612.3) | (536.2) | (496.2) | (324.2) | (186.3) | (93.9) | (98.9) | (88.9) | (113.4) | 18.7 | (37.4) | (14.8) | (33.9) | (40.5) | (48.0) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 45.6 | 37.7 | 28.3 | 19.4 | 16.4 | 16.0 | 6.6 | 3.8 | 3.0 | 2.7 | — | 0.0 | 0.0 | 0.0 | — |
| Interest & Investment Income | — | — | — | — | 11.4 | 1.0 | 5.3 | 4.5 | — | — | 0.4 | 0.2 | 0.1 | 0.1 | 0.1 | — |
| Net Interest Expenses | — | — | — | — | 8.0 | 15.4 | 10.7 | 2.1 | — | — | 2.2 | — | (0.1) | (0.1) | (0.1) | — |
| Other Non-Operating Income / Expenses | 46.7 | 48.4 | 51.5 | 27.6 | 11.3 | 0.3 | 5.3 | 4.5 | 4.2 | 2.6 | 0.5 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 |
| EBT, Incl. Unusual Items | — | — | — | — | — | — | — | — | (106.3) | (127.8) | 16.5 | (37.5) | (14.6) | (33.7) | (40.4) | (47.9) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | 0.0 | (0.2) |
| Net Income | ||||||||||||||||
| Net Income | (894.0) | (785.0) | (589.5) | (526.2) | (389.0) | (215.3) | (127.3) | (121.7) | (106.3) | (127.8) | 16.5 | (37.5) | (14.6) | (33.7) | (40.4) | (47.9) |
| Per Share | ||||||||||||||||
| Basic EPS | (6,768.33) | (6.54) | (5.26) | (5.45) | (4.33) | (2.80) | (1.97) | — | — | (2.59) | 0.41 | — | — | — | — | (0.72) |
| Diluted EPS | (6,768.33) | (6.54) | (5.26) | (5.45) | (4.33) | (2.80) | (1.97) | — | — | (2.59) | 0.39 | — | — | — | — | (0.72) |
| Revenue per Share | 512.32 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | — | — | 49.4 | 39.9 | — | — | — | 108.6 | 70.8 |
| Diluted Weighted Avg Shares | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | — | — | 49.4 | 42.6 | — | — | — | — | 70.8 |
| Supplemental | ||||||||||||||||
| EBITDA | — | (602.1) | (526.7) | (484.3) | (318.4) | (184.0) | (92.1) | (97.6) | (87.7) | (111.5) | 19.4 | (36.8) | (14.3) | (33.5) | (39.9) | (46.7) |
| EBIT | (707.9) | (612.3) | (536.2) | (496.2) | (324.2) | (186.3) | (93.9) | (98.9) | (88.9) | (113.4) | 18.7 | (37.4) | (14.8) | (33.9) | (40.5) | (48.0) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.4% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.